Skip to content
Research Article Open access CC BY 4.0

Determination of pKa and Degradation Products of the Mutated BRAF Inhibitor Vemurafenib and UPLC Assay in Human Urine

Senem Şanli, Ayşe Özdemir, Gülşen Güven, Süleyman Gökçe

Journal of Pharmaceutical Research International · pp. 18–27 · Published 19 Dec 2020

10.9734/jpri/2020/v32i3630986

Abstract

In this study, the pKa value of vemurafenib was determined by the dependence of the retention factor on the pH of the mobile phase. The change of pKa in the different acetonitrile fraction ranging between 57.5 and 62.5% (v/v) was studied by using an LC-UV method. Additionally, a simple, reliable, and rapid UPLC method has been developed for the determination of vemurafenib in human urine. Efavirenz was used as an internal standart. For vemurafenib and efavirenz, selectivity factors were found as 1.204. The asymmetry and capacity factors were obtained as 1.100 and 7.532 for vemurafenib. Vemurafenib was exposed to thermal, photolytic, hydrolytic, and oxidative stress conditions, and the stressed samples were detected by LC/MS/MS method.

Vemurafenib UPLC pKa degradation products urine.

Cited by 1

Environmental degradation of the anticancer drug encorafenib: Evidence for cyclisation through aromatic ring flip under photolytic conditions

Srinivas Reddy Dannarm, Bharath Reddy Gottimukkula, Choudhary Sampat Dhalaram · Microchemical journal (Print) · 2025

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

1

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.